Drug Profile
ImmunoKine
Alternative Names: Immunomodulatory proteinsLatest Information Update: 10 Mar 2011
Price :
$50
*
At a glance
- Originator GeneTrol Biotherapeutics
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 10 Mar 2011 No development reported - Preclinical for Multiple sclerosis in USA (unspecified route)
- 15 Dec 2004 This profile is still in active development
- 30 Oct 2001 Preclinical development for Multiple sclerosis in USA (Unknown route)